Cyclacel up 26% as data on sapacitabine to be announced soon
Cyclacel Pharmaceuticals $CYCC is up on 5x volume despite no immediate news; however, major upcoming catalyst, by year end or so, is topline data from p3 trial of oral sapacitabine as first-line treatment of patients at least 70 years old with acute myeloid leukemia.
Northwest Bio starts p2 study of DCVax/Keytruda combo in advanced colorectal cancer
Northwest Biotherapeutics $NWBO is starting a Phase 2 clinical trial for the combo of DCVax-L and Merck's $MRKPD-1 inhibitor Keytruda (pembrolizumab) in patients with colorectal cancer with liver metastases. Regulatory approval yet to be received.
Endo up on positive CCH data
Endo International $ENDP announced positive data from a Phase 2b clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), or cellulite. The 375 adult women patient study showed highly statistically significant improvement in the appearance of cellulite.
CCH is marketed in the U.S. as XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease.
Keryx Bio additional data of Auryxia study in iron deficiency anemia
Keryx Biopharmaceuticals $KERX presented p3 data for Auryxia (ferric citrate) for the treatment of iron deficiency in adults with stage 3-5 non-dialysis-dependent chronic kidney disease (CKD). The study met its primary and secondary endpoints. 52% (n=61/117) of participants achieved at least a 1 g/dL increase in hemoglobin at some point in the 16-week efficacy period and 93.4% (n=57/61) of these patients experienced a sustained treatment effect.
Auryxia was approved in the U.S. in September 2014 for the control of serum phosphorus levels in CKD patients on dialysis.
ZIOPHARM gene therapy with RheoSwitch suicide switch shows encouraging results in early-stage brain cancer study
Interim results from a Phase 1 study of $ZIOP gene therapy candidate with RheoSwitch showed median OS of almost 13 months and treatment was well-tolerated.
However, TheStreet's Adam Feuerstein says that nine of the 17 patients that are the basis for OS data were censored before the median and that the data is not correct.